KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial

(University of Texas M. D. Anderson Cancer Center) For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study.